329 related articles for article (PubMed ID: 19962915)
1. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
Wong KK; Cahill JM; Frey KA; Avram AM
Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
[TBL] [Abstract][Full Text] [Related]
2. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.
Chen L; Luo Q; Shen Y; Yu Y; Yuan Z; Lu H; Zhu R
J Nucl Med; 2008 Dec; 49(12):1952-7. PubMed ID: 18997044
[TBL] [Abstract][Full Text] [Related]
3. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma.
Wong KK; Zarzhevsky N; Cahill JM; Frey KA; Avram AM
AJR Am J Roentgenol; 2008 Dec; 191(6):1785-94. PubMed ID: 19020251
[TBL] [Abstract][Full Text] [Related]
4. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis.
Ingui CJ; Shah NP; Oates ME
Clin Nucl Med; 2006 Nov; 31(11):665-72. PubMed ID: 17053381
[TBL] [Abstract][Full Text] [Related]
5. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
7. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
Ruf J; Steffen I; Mehl S; Rosner C; Denecke T; Pape UF; Plotkin M; Amthauer H
Nucl Med Commun; 2007 Oct; 28(10):782-8. PubMed ID: 17728608
[TBL] [Abstract][Full Text] [Related]
8. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.
Wang H; Fu HL; Li JN; Zou RJ; Gu ZH; Wu JC
Clin Imaging; 2009; 33(1):49-54. PubMed ID: 19135930
[TBL] [Abstract][Full Text] [Related]
9. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
10. SPECT/CT imaging using a spiral CT scanner for anatomical localization: Impact on diagnostic accuracy and reporter confidence in clinical practice.
Roach PJ; Schembri GP; Ho Shon IA; Bailey EA; Bailey DL
Nucl Med Commun; 2006 Dec; 27(12):977-87. PubMed ID: 17088684
[TBL] [Abstract][Full Text] [Related]
11. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement.
Apostolova I; Riethdorf S; Buchert R; Derlin T; Brenner W; Mester J; Klutmann S
Ann Nucl Med; 2010 Jul; 24(6):477-83. PubMed ID: 20449694
[TBL] [Abstract][Full Text] [Related]
12. Cardiac image fusion from stand-alone SPECT and CT: clinical experience.
Gaemperli O; Schepis T; Valenta I; Husmann L; Scheffel H; Duerst V; Eberli FR; Luscher TF; Alkadhi H; Kaufmann PA
J Nucl Med; 2007 May; 48(5):696-703. PubMed ID: 17475956
[TBL] [Abstract][Full Text] [Related]
13. Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism.
Neumann DR; Obuchowski NA; Difilippo FP
J Nucl Med; 2008 Dec; 49(12):2012-7. PubMed ID: 18997051
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of SPECT/CT with In-111 biotin on the management of patients with suspected spine infection.
Lazzeri E; Erba P; Perri M; Doria R; Tascini C; Mariani G
Clin Nucl Med; 2010 Jan; 35(1):12-7. PubMed ID: 20026965
[TBL] [Abstract][Full Text] [Related]
16. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
17. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne.
Pérault C; Schvartz C; Wampach H; Liehn JC; Delisle MJ
J Nucl Med; 1997 Aug; 38(8):1234-42. PubMed ID: 9255157
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
[TBL] [Abstract][Full Text] [Related]
19. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
20. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
